Enzo Biochem (ENZ) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enzo Biochem Reports Strong First Quarter
December 7, 2015 4:15 PM ESTExecution on Corporate Strategy seen in Companys Results
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc. (NYSE: ENZ) today reported another period of strong results for the first fiscal quarter ended October 31, 2015.
First Quarter Highlights
Strong financial performance at Enzo Clinical Labs and new legal settlements contributes to year-over year revenues and net income gains. Total Revenue was $25.2 million with Clinical Lab Revenue of $17.1 million up 8% over prior year. Gross margins at the Lab climbed to 40%, an increase of 400 basis... More